Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.063 | 0.7 |
mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.066 | 0.7 |
mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |